Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), announced today that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot FDA News Management Comments Trading Halts

Needham & Company Downgrades Pacira Pharmaceuticals (PCRX) to HoldFebruary 16, 2018 7:20 AM Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO CapitalFebruary 16, 2018 6:11 AM Pacira Pharma (PCRX) to Resume Trading at 4:15 pm ETFebruary 15, 2018 3:51 PM Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional AnalgesiaFebruary 15, 2018 3:35 PM Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional AnalgesiaFebruary 15, 2018 3:34 PM Pacira Pharma (PCRX) Doesn't Win FDA Panel Backing of EXPAREL in 6 to 4 Vote Against Approval February 15, 2018 3:01 PM